Using of checkpoint inhibitors as a treatment for melanoma
Immune checkpoint inhibitors are drugs that help the immune system to release “brakes” of inhibitory receptors expressed on the surface of activated T-cells, cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death receptor 1 (PD-1) that enhances T-cell-mediated antitumor immune responses leading to improved immune responses. Ipilimumab and Nivolumab are examples of immune checkpoint inhibitors, where ipilimumab targets CTLA-4 and nivolumab targets PD1/PD-L1
Other
Immune checkpoint blockade has used as a treatment of patients with advanced melanoma and many other cancers. Blockade of inhibitory receptors, cytotoxic Tlymphocyte antigen 4 (CTLA-4) and programmed cell death receptor 1 (PD-1) that enhances T-cell-mediated antitumor immune responses leading to improved immune responses, based on their studies and mechanism of action in the treatment of metastatic melanoma
